TOP: Tysabri® Observational Program

Trial Profile

TOP: Tysabri® Observational Program

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2017

At a glance

  • Drugs Natalizumab (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms TOP
  • Sponsors Biogen
  • Most Recent Events

    • 01 Nov 2017 Results of pooled retrospective analysis assessing natalizumab-associated progressive multifocal leukoencephalopathy from four observational studies (STRATIFY-2, STRATA, TOP, and TYGRIS) published in the Lancet Neurology.
    • 28 Oct 2017 Results (n=1204; Data cut off 1 November 2016) of analysis characterising confirmed disability improvement presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results (n= 2466; as of 1 Nov 2016) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top